Bristol-Myers Squibb Company
時価総額
$132.0B
世界順位
#127
過去最高値
$134.6B
2026-08-04
総成長率
+0%
2026年以降
Market Cap Context
- Larger than 65% of the 367 companies we track (globally).
- Equivalent to 0.4% of United States's GDP (2025 data).
- Just above: #126 Prologis, Inc. ($133.6B)
- Just below: #128 BNP Paribas SA ($131.6B)
- Best year: 1997 (+78%). Worst year: 2002 (-53%).
Bristol-Myers Squibb Company Financial Breakdown (FY 2025)
Source: Yahoo Finance — BMY annual filings (2025) →$48.2B revenue · $13.7B operating income · $7.1B net income
- ●Operating margin: 28.5% on $48.2B in revenue.
- ●R&D is 20.6% of revenue ($10.0B).
- ●Net income margin: 14.6% — $7.1B in profit.
- ●Free cash flow: $12.8B (26.7% of revenue).
Cost / Operating Expenses
Total operating expenses $34.5B
Total
$31.2B
Capital Expenditures
$1.3B
This fiscal year (near-total AI infrastructure buildout)
Free Cash Flow
$12.8B
Trailing twelve months
Figures rounded from the annual SEC filing. Unaudited. For informational purposes only, not investment advice.
Bristol-Myers Squibb Companyについて
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation ; nivolumab (Opdivo), used to treat certain types of cancer ; lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes ; abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid arthritis ; pomalidomide (Pomalyst/Imnovid), an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma ; ipilimumab (Yervoy), to treat cancer ; and luspatercept (Reblozyl) for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2025, 69% of the company's revenues came from the United States.
Bristol-Myers Squibb Companyの時価総額推移 (2026–2026)
Bristol-Myers Squibb Company vs Sector Peers by Market Cap
Bristol-Myers Squibb Companyを比較
順位の推移
| 年 | 時価総額 | 順位 | 前年比 |
|---|---|---|---|
| 2026 | $132.0B | #127(↑12) | +22.5% |
| 2025 | $107.8B | #139(↓15) | +0.1% |
| 2024 | $107.6B | #124(↓3) | +15.8% |
| 2023 | $92.9B | #121(↓53) | -26.1% |
| 2022 | $125.8B | #68(↑26) | +19.0% |
| 2021 | $105.8B | #94(↓13) | +3.7% |
| 2020 | $102.0B | #81(↓14) | -0.4% |
| 2019 | $102.4B | #67(↓6) | +27.7% |
| 2018 | $80.2B | #61(↓9) | -12.9% |
| 2017 | $92.0B | #52(↓6) | +7.7% |
| 2016 | $85.4B | #46(↓17) | -13.0% |
| 2015 | $98.2B | #29(↑11) | +19.3% |
| 2014 | $82.3B | #40(↑2) | +14.2% |
| 2013 | $72.0B | #42(↑16) | +68.8% |
| 2012 | $42.7B | #58(↓15) | -3.8% |
| 2011 | $44.4B | #43(↑24) | +39.4% |
| 2010 | $31.8B | #67 | +10.1% |
| 2009 | $28.9B | #67(↓14) | +15.0% |
| 2008 | $25.1B | #53(↑28) | -7.3% |
| 2007 | $27.1B | #81(↓13) | +4.8% |
| 2006 | $25.9B | #68(↑4) | +19.9% |
| 2005 | $21.6B | #72(↓11) | -6.1% |
| 2004 | $23.0B | #61(↓15) | -6.3% |
| 2003 | $24.5B | #46(↓3) | +29.4% |
| 2002 | $19.0B | #43(↓18) | -53.0% |
| 2001 | $40.3B | #25(↓4) | -26.2% |
| 2000 | $54.6B | #21(↑4) | +17.1% |
| 1999 | $46.6B | #25(↓8) | -2.8% |
| 1998 | $48.0B | #17(↑2) | +43.6% |
| 1997 | $33.4B | #19(↑9) | +77.5% |
| 1996 | $18.8B | #28(↓2) | +31.2% |
| 1995 | $14.3B | #26(↓1) | +55.2% |
| 1994 | $9.2B | #25 |
その他のヘルスケア企業
よくある質問
What is Bristol-Myers Squibb Company's market cap?
Bristol-Myers Squibb Company (BMY) has a market capitalization of $132.0B, making it the #127 largest company in the world by market cap.
What was Bristol-Myers Squibb Company's highest market cap?
Bristol-Myers Squibb Company's all-time high market cap was $134.6B, reached in 2026-08-04. Its highest rank was #127 in 2026.
What sector is Bristol-Myers Squibb Company in?
Bristol-Myers Squibb Company is in the Healthcare sector, specifically the Drug Manufacturers - General industry. It is based in United States.
How has Bristol-Myers Squibb Company's market cap changed over time?
Bristol-Myers Squibb Company has been tracked since 2026. Its market cap has grown by 0% from $132.0B in 2026 to $132.0B today.